Michael Wacker

About

Michael is an experienced life science entrepreneur who joined Biomed in 2019. Michael successfully built up various start-up companies. In addition, he coaches start-ups in Switzerland for Innosuisse, the governmental commission of technology and innovation. Previously he was chairman of Inositec (acquired by Vifor Pharma) and board member and chief business officer of Polyneuron Pharmaceuticals, a spin-off company of the university of Basel. Before joining Polyneuron, he was founder, board member and CSO of GlycoVaxyn, a vaccine development company that was acquired by GSK in 2015 and which valued the company at $212 million. Michael co-founded GlycoVaxyn in 2004 as a Spin-off company from the Swiss Federal Institute of Technology Zurich (ETHZ). Michael holds a M.Sc. in biochemistry and completed his Ph.D. and post-doctoral fellowship in microbiology at ETHZ. He is the author of several publications in international scientific journals, including Science and PNAS, as well as inventor

Source (opens in a new tab)